The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)
Cancers · 14.02.2024 · 16 (4) · 775
DOI: 10.3390/cancers16040775 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.02.2024. Verfasst von Daniela Fischerova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General Univers…. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic.
Abstract (Originalsprache)
Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques. After five years (2023), an update of the ESGO-ESTRO-ESP recommendations was performed, further confirming this statement. Transvaginal/transrectal ultrasound (TRS/TVS) or pelvic magnetic resonance (MRI) enables tumor delineation and precise assessment of its local extent, including the evaluation of the depth of infiltration in the bladder- or rectal wall. Additionally, both techniques have very high specificity to confirm the presence of metastatic pelvic lymph nodes but fail to exclude them due to insufficient sensitivity to detect small-volume metastases, as in any other currently available imaging modality. In early-stage disease (T1a to T2a1, except T1b3) with negative lymph nodes on TVS/TRS or MRI, surgicopathological staging should be performed. In all other situations, contrast-enhanced computed tomography (CECT) or 18F-fluorodeoxyglucose positron emission tomography combined with CT (PET-CT) is recommended to assess extrapelvic spread. This paper aims to review the evidence supporting the implementation of diagnostic imaging with a focus on ultrasound at primary diagnostic workup of cervical cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic.
- Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic.
- Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, N-5021 Bergen, Norway.
- Section for Radiology, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.
- Department of Biomedical Science for Health, University of Milan, 20133 Milan, Italy.
ORCID-Profile: Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S Haldorsen, Elena Gatti
Förderung
- Ministry of Health of the Czech Republic
Zitieren
APA
Fischerova, D., Frühauf, F., Burgetova, A., Haldorsen, I. S., Gatti, E., & Cibula, D. (2024). The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023). Cancers, 16(4), 775. https://doi.org/10.3390/cancers16040775
Vancouver
Fischerova D, Frühauf F, Burgetova A, Haldorsen IS, Gatti E, Cibula D. The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023). Cancers. 2024;16(4):775. doi:10.3390/cancers16040775
BibTeX
@article{Fischerova2024,
author = {Fischerova, Daniela and Frühauf, Filip and Burgetova, Andrea and Haldorsen, Ingfrid S and Gatti, Elena and Cibula, David},
title = {The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {775},
doi = {10.3390/cancers16040775}
}
EUVIMED